Wilson EC, et al. - Researchers assessed hepatitis C virus (HCV) prevalence among transwomen in San Francisco via performing a cross-sectional survey. Further, they assessed the indicators of engagement in HCV care. They interviewed a total of 315 transwomen who were then tested for HCV antibodies. Outcomes revealed an overall HCV seroprevalence of 23.6%. Transwomen who had injected drugs (48.2% vs 9.9%), smoked crack or methamphetamine (30.8% vs 12.5%), used intranasal drugs (28.4% vs 15.8%), and had been incarcerated (27.9% vs 9.9%) displayed significantly higher HCV seroprevalence. Overall, transwomen are at high risk for HCV infection, but many in San Francisco do have access to testing and treatment services, which may allow for HCV control and elimination.